Publicacións en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (107)

2024

  1. Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning

    RMD Open, Vol. 10, Núm. 1

  2. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  3. Similarities and differences between systemic juvenile idiopathic arthritis and adult-onset Still’s disease: a multicenter Spanish study

    Rheumatology International

2023

  1. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 61

  2. What do patients on methotrexate need and expect at the clinic? An online patient survey

    Rheumatology International, Vol. 43, Núm. 4, pp. 735-741

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

  3. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  4. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology

    Reumatologia Clinica, Vol. 18, Núm. 5, pp. 253-259

  5. Patient's experiences of the barriers and facilitators to Methotrexate

    Musculoskeletal Care, Vol. 20, Núm. 1, pp. 158-166

  6. Use of Parenteral Methotrexate in Rheumatic Diseases: A Systematic Review

    Reumatologia Clinica, Vol. 18, Núm. 4, pp. 207-226

  7. Validation of screening criteria for spondyloarthritis in patients with inflammatory bowel disease in routine clinical practice

    Digestive and Liver Disease, Vol. 54, Núm. 6, pp. 755-762

2021

  1. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1137-1146

  2. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

  3. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  4. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

  5. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study

    RMD Open, Vol. 7, Núm. 3

  6. The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA–B27 Status?

    Arthritis Care and Research, Vol. 73, Núm. 6, pp. 856-860

  7. Treatment with tofacitinib in refractory psoriatic arthritis: A national multicenter study of the first 87 patients in clinical practice

    Journal of Rheumatology, Vol. 48, Núm. 10, pp. 1552-1558

  8. Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 160-169